Home / Resources / Early Clinical resources

早期临床

精选资源

Advancing Bayesian Methods in Clinical Trials

Press Coverage, Video

Upcoming early clinical webinars

网络研讨会

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Mar 17, Apr 2 – 11am - 12pm ET

网络研讨会

Explore Smarter, Faster PK/PD with Phoenix

2026 年 3 月 17 日 – 10-11 AM ET/CET/JST

网络研讨会

Simcyp® Simulator Version 25: Streamline Drug Development with Regulatory-Compliant PBPK

2026 年 3 月 19 日 - 9:00-10:00am 北京时间

Latest early clinical blogs

All Early clinical - Blog

Blog

降低药物开发风险：早期开发中的关键化学、制造和控制（CMC）及基于生理的药代动力学（PBPK）方法

在以下活动中与我们的专家会面

会议

ACDM 2026

2026 年 3 月 15 - 17 日 - 德国柏林 - Booth 13

会议

Apotekarsocieteten 临床药理学策略在药物开发中的应用

2026 年 3 月 17 日

会议

SOT Annual Meeting and ToxExpo 2026

March 22 - 25, 2026 – San Diego, CA – Booth 2024

All early clinical resources

Population Pharmacokinetic Analysis of Dutogliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor

Endocrinology, Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Application of a Physiologically-based Pharmacokinetic Model to Predict OATP1B1-related Variability in Pharmacodynamics of Rosuvastatin

Certara Products, Clinical Trials, Clinical Trials Software, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, pre-update, Publication

A Re-evaluation and Validation of Ontogeny Functions for CYPs 1A2 and 3A4 Based on In Vivo Data

Model Informed Drug Development, Pediatrics, pre-update, Therapeutic Specialties, Publication

Animal Versus Human Oral Drug Bioavailability: Do They Correlate?

Model Informed Drug Development, pre-update, Publication

Quantitative Prediction of Formulation-specific Food Effects and Their Population Variability from In Vitro Data Using the Physiologically-based ADAM Model: A Case Study Using BCS/BDDCS Class II Drug Nifedipine.

Model Informed Drug Development, pre-update, Publication

Conversion from Twice- to Once-daily Tacrolimus in Pediatric Kidney Recipients: A Pharmacokinetic and Bioequivalence Study

Pediatrics, pre-update, Therapeutic Specialties, Publication

The ISoP Standards and Best Practices Committee

Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Publication

What Can We Learn from Dose Normalization?

Modeling and Simulation - PK/PD, Blog, Knowledge Base

Improving the Assessment of Heart Toxicity for All New Drugs Through Translational Regulatory Science

Model Informed Drug Development, pre-update, Publication

Changes in Individual Drug-independent System Parameters during Virtual Pediatric Pharmacokinetic Trials: Introducing Time-varying Physiology into a Pediatric PBPK Model

Model Informed Drug Development, Pediatrics, pre-update, Therapeutic Specialties, Publication

Physiologically-based Pharmacokinetic Modeling Framework for Quantitative Prediction of an Herb–Drug Interaction

Modeling and Simulation - PK/PD, pre-update, Publication

Population Pharmacokinetics of Azithromycin in Whole Blood, Peripheral Blood Mononuclear Cells, and Polymorphonuclear Cells in Healthy Adults

Infectious Disease, Model Informed Drug Development, Modeling and Simulation - PK/PD, Oncology/Hematology, pre-update, Therapeutic Specialties, Publication

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

早期临床

最新资源

FDA Support Drives Shift Toward Bayesian Trial Design

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

精选资源

Advancing Bayesian Methods in Clinical Trials

Upcoming early clinical webinars

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Explore Smarter, Faster PK/PD with Phoenix

Simcyp® Simulator Version 25: Streamline Drug Development with Regulatory-Compliant PBPK

Latest early clinical blogs

药物开发中 PK/PD 建模的机器学习

美国 FDA MIDD 配对试点计划如何帮助赞助商

揭秘临床 DDI 研究：精准测量代谢产物

为何 FDA 批准 omaveloxolone 用于治疗弗里德赖希共济失调症意义重大

细胞疗法开发的主要考虑因素

降低药物开发风险：早期开发中的关键化学、制造和控制（CMC）及基于生理的药代动力学（PBPK）方法

在以下活动中与我们的专家会面

ACDM 2026

Apotekarsocieteten 临床药理学策略在药物开发中的应用

SOT Annual Meeting and ToxExpo 2026

All early clinical resources

Population Pharmacokinetic Analysis of Dutogliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor

Application of a Physiologically-based Pharmacokinetic Model to Predict OATP1B1-related Variability in Pharmacodynamics of Rosuvastatin

A Re-evaluation and Validation of Ontogeny Functions for CYPs 1A2 and 3A4 Based on In Vivo Data

Animal Versus Human Oral Drug Bioavailability: Do They Correlate?

Quantitative Prediction of Formulation-specific Food Effects and Their Population Variability from In Vitro Data Using the Physiologically-based ADAM Model: A Case Study Using BCS/BDDCS Class II Drug Nifedipine.

Conversion from Twice- to Once-daily Tacrolimus in Pediatric Kidney Recipients: A Pharmacokinetic and Bioequivalence Study

The ISoP Standards and Best Practices Committee

What Can We Learn from Dose Normalization?

Improving the Assessment of Heart Toxicity for All New Drugs Through Translational Regulatory Science

Changes in Individual Drug-independent System Parameters during Virtual Pediatric Pharmacokinetic Trials: Introducing Time-varying Physiology into a Pediatric PBPK Model

Physiologically-based Pharmacokinetic Modeling Framework for Quantitative Prediction of an Herb–Drug Interaction

Population Pharmacokinetics of Azithromycin in Whole Blood, Peripheral Blood Mononuclear Cells, and Polymorphonuclear Cells in Healthy Adults

订阅时事通讯

快捷链接

解决方案

联系我们